The discovery that a series of N,N-dialkyl-N'-arylureas were inhibitors of the ACAT enzyme has led to a structure-activity study involving the systematic modification of three sites of the urea backbone.This study culminated in the selection of N'-(2,4-dimethylphenyl)-N-benzyl-N-n-butylurea (115) for more extensive biological evaluation.ACAT inhibitors are seen as potentially beneficial agents against hypercholesterolemia and atherosclerosis.
DeVries, Vern G.,Bloom, Jonathan D.,Dutia, Minu D.,Katocs, Andrew S.,Largis, Elwood E.
p. 2318 - 2325
(2007/10/02)
More Articles about upstream products of 122020-56-8